Idogen develops tolerogenic cell therapies to counteract attacks by the patient’s immune system on biological agents, transplanted organs or the body’s own cells or tissue. The term ‘tolerogenic’ refers to the immune system’s selective tolerance of a specific pathogenic or immunostimulatory antigen following treatment with Idogen’s cell therapy. Idogen’s most advanced product candidate, IDO 8, is designed for patients with severe hemophilia A who have developed neutralizing antibodies against their life-saving therapy with coagulation factor VIII (FVIII).

HEADQUARTER
Idogen
Medicon Village, Scheelevägen 2, SE-223 81 Lund, Sweden

WEBSITE
https://idogen.com